Bruker Reports Third Quarter 2026 Financial Results

BRUKER CORP (BRKR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Bruker Reports Third Quarter 2026 Financial Results • Q3-26 revenue of $874.0 million, up 1.6% yoy; up 0.7% organically • Q3-26 non-GAAP operating margin of 16.3%, up 400 bps yoy • Q3-26 GAAP diluted Loss Per Share of $(0.81); non-GAAP diluted EPS of $0.56, up 24.4% yoy • Reconfi

Event · Earnings
Also in this documentGuidance · reaffirm · $2.1–$2.15

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 4, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 12:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$BRKR
Bullish
high confidence
Mentioned
$BRKR
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$BRKRBullishMed
01

Why it matters

The reaffirmed guidance suggests stability but does not raise expectations, limiting immediate trade urgency.

02

Market read

Earnings and guidance reaffirmation are the primary drivers; sector peers may be affected by comparative performance.

03

What to watch

Potential headwinds from foreign‑currency translation losses and goodwill impairment charges could temper earnings quality.

Relevance 8/10Novelty 8/10Timing: today
AlphAI · Earnings readBRKR · Q3-26 · ended September 30, 2026

Q3-26 revenue of $874.0 million, up 1.6% yoy; non-GAAP operating margin of 16.3%, up 400 bps yoy; non-GAAP diluted EPS of $0.56, up 24.4% yoy

→Mixed quarter

Revenue growth was 1.6% and organic revenue growth was 0.7%, while BSI organic revenue declined 0.4%. Non-GAAP operating margin expanded to 16.3% and non-GAAP diluted EPS increased 24.4%, but GAAP results included a $174.5 million non-cash goodwill impairment charge and a GAAP operating loss of $(91.0) million.

Revenue
$874M
1.6% y/y
Bruker BIOS
$397M
FY26 outlook
$3.52 to $3.56 billion

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Q3-26 total revenueGAAP$874M–1.6%
Q3-26 organic revenuenon-GAAP$866.2M–0.7%
Q3-26 CER currency revenuenon-GAAP$881.2M–2.4%
Q3-26 gross profitGAAP$429.3M––
Q3-26 gross profit marginGAAP49.1%––
Q3-26 gross profitnon-GAAP$448.3M––
Q3-26 gross profit marginnon-GAAP51.3%––
Q3-26 selling, general and administrative expensesGAAP$226.5M––
Q3-26 research and development expensesGAAP$92M––
Q3-26 total operating expensesGAAP$520.3M––
Q3-26 operating lossGAAP−$91M––
Q3-26 operating loss marginGAAP(10.4)%––
Q3-26 operating incomenon-GAAP$142.6M––
Q3-26 operating income marginnon-GAAP16.3%–up 400 bps yoy
Q3-26 net loss attributable to Bruker Corporation common shareholdersGAAP−$122.8M––
Q3-26 net income attributable to Bruker Corporation common shareholdersnon-GAAP$86.3M––
Q3-26 diluted loss per common share attributable to Bruker Corporation common shareholdersGAAP$(0.81)––
Q3-26 diluted net income per common share attributable to Bruker Corporation common shareholdersnon-GAAP$0.56–24.4%
Q3-26 net cash provided by operating activitiesGAAP$118.2M––
Q3-26 free cash flownon-GAAP$96.7M––
First nine months of 2026 total revenueGAAP$2.54B–3.1%
First nine months of 2026 organic revenuenon-GAAP$2.45B–(0.3)%
First nine months of 2026 gross profitGAAP$1.23B––
First nine months of 2026 gross profit marginGAAP48.3%––
First nine months of 2026 operating lossGAAP−$146.1M––
First nine months of 2026 operating incomenon-GAAP$345.3M––
First nine months of 2026 operating income marginnon-GAAP13.6%––
First nine months of 2026 net loss attributable to Bruker Corporation common shareholdersGAAP−$182.2M––
First nine months of 2026 net income attributable to Bruker Corporation common shareholdersnon-GAAP$208.7M––
First nine months of 2026 diluted loss per common share attributable to Bruker Corporation common shareholdersGAAP$(1.20)––
First nine months of 2026 diluted net income per common share attributable to Bruker Corporation common shareholdersnon-GAAP$1.36––
First nine months of 2026 net cash provided by operating activitiesGAAP$112M––
First nine months of 2026 free cash flownon-GAAP$37.5M––

Segments

SegmentRevenueq/qy/y
Bruker BIOSNot stated$397.2M––
Bruker MIDNot stated$133.6M––
Bruker NanoNot stated$263.1M––
BSI Revenue TotalOrganic revenue decreased by 0.4% yoy.$793.9M–0.8%
BESTOrganic revenue increased 11.8%, net of intercompany eliminations.$82.1M–11.2%

FY26 outlook

  • Revenue$3.52 to $3.56 billion
  • NoteFY25 revenues of $3.44 billion
  • Note2.5% to 3.5% year-over-year reported revenue growth
  • NoteOrganic revenue growth of 1% to 2%
  • NoteM&A revenue growth of approximately 1.5%
  • NoteCER revenue growth of 2.5% to 3.5%
  • NoteForeign currency neutral to revenue (previously a tailwind of 0.5%)
  • NoteFY26 non-GAAP EPS of $2.10 to $2.15 compared to $1.83 in FY25
  • Note15% to 17% year-over-year increase in FY26 non-GAAP EPS

Capital returns

  • Payment of dividends to shareholders of $(18.7) million in the three months ended September 30, 2026.
  • Payment of dividends to shareholders of $(55.8) million in the nine months ended September 30, 2026.

What drove it

  • Q3-26 acquisitions contributed 1.7% to revenue growth.
  • Foreign currency translation had an unfavorable impact of -0.8% yoy on Q3-26 revenue.
  • Q3-26 BEST organic revenue increased 11.8%, net of intercompany eliminations.
  • Management cited cost discipline and execution as drivers of margin expansion and non-GAAP EPS growth.
  • Management said BSI book-to-bill was greater than one for the fifth consecutive quarter.
  • Management said BSI organic bookings and backlog were both up mid-single digits % year-to-date.

Concerns

  • Q3-26 BSI organic revenue decreased by 0.4% yoy.
  • First nine months of 2026 organic revenue decreased by 0.3% yoy, and BSI organic revenue decreased by 1.0%.
  • Q3-26 GAAP operating loss was $(91.0) million and included $174.5 million of non-cash goodwill impairment charges.
  • First nine months of 2026 GAAP operating loss was $(146.1) million, compared to $(8.1) million in the first nine months of 2025.
  • Foreign currency translation was expected to be neutral to FY26 revenue, updated from a previously expected tailwind of 0.5%.

What to watch

  • Progress toward FY26 organic revenue growth of 1% to 2%.
  • Whether BSI booking and backlog trends translate into the revenue growth acceleration management expects.
  • Sustainability of non-GAAP operating margin expansion after Q3-26 margin reached 16.3%.
  • Foreign currency effects, which reduced Q3-26 reported revenue growth by -0.8% yoy.
  • The impact of the goodwill impairment charges on GAAP profitability.

Balance sheet and cash flow

  • Cash and cash equivalents were $119.7 million as of September 30, 2026, compared to $298.8 million as of December 31, 2025.
  • Long-term debt was $1,703.0 million as of September 30, 2026, compared to $1,852.5 million as of December 31, 2025.
  • Current portion of long-term debt and finance lease obligations was $10.4 million as of September 30, 2026, compared to $16.6 million as of December 31, 2025.
  • Purchases of property, plant and equipment and intangible assets were $(21.5) million in Q3-26 and $(74.5) million in the first nine months of 2026.
  • Cash paid for acquisitions, net of cash acquired, was $(57.0) million in Q3-26 and $(73.0) million in the first nine months of 2026.
  • Repayment of long-term debt was $(2.7) million in Q3-26 and $(186.3) million in the first nine months of 2026.

Analysis

Bruker reported Q3-26 revenue of $874.0 million, up 1.6% yoy, with organic revenue growth of 0.7%. Acquisitions contributed 1.7% to growth, while foreign currency translation reduced revenue by -0.8% yoy. The first nine months showed $2,535.9 million of revenue, up 3.1%, but organic revenue decreased by 0.3%, highlighting the limited underlying growth across the year to date.

Segment performance was uneven. BSI revenue was $793.9 million, up 0.8% yoy, but BSI organic revenue decreased by 0.4%. BEST generated $82.1 million of revenue, up 11.2% yoy, with 11.8% organic growth net of intercompany eliminations. Management pointed to a fifth consecutive quarter of BSI book-to-bill greater than one, strengthening demand in most end markets and BSI organic bookings and backlog both up mid-single digits % year-to-date.

Profitability improved materially on a non-GAAP basis. Q3-26 non-GAAP operating income increased to $142.6 million from $105.9 million, and non-GAAP operating margin expanded to 16.3% from 12.3%. Non-GAAP diluted EPS rose to $0.56 from $0.45. GAAP results remained sharply negative, however, as Q3-26 included $174.5 million of non-cash goodwill impairment charges, producing a GAAP operating loss of $(91.0) million and GAAP diluted loss per share of $(0.81).

Cash flow improved versus the prior-year period. Q3-26 net cash provided by operating activities was $118.2 million and free cash flow was $96.7 million, compared with $(33.2) million and $(54.1) million, respectively, a year earlier. Cash and cash equivalents were $119.7 million at September 30, 2026, while long-term debt was $1,703.0 million. The company paid $(18.7) million of shareholder dividends in Q3-26 and $(55.8) million in the first nine months.

Bruker reconfirmed FY26 organic revenue growth and non-GAAP EPS guidance while updating currency assumptions. It expects FY26 revenue of $3.52 to $3.56 billion, including 1% to 2% organic growth, and FY26 non-GAAP EPS of $2.10 to $2.15. Foreign currency is now expected to be neutral to revenue rather than a tailwind of 0.5%, placing greater weight on the anticipated conversion of BSI bookings and backlog into organic growth and on continued margin execution.

Management, verbatim

In the third quarter, we achieved very significant margin expansion and non-GAAP EPS growth, driven by our focus on cost discipline and execution.

Frank H. Laukien, President and CEO

Bruker’s positive booking trends continued with the fifth consecutive quarter of Bruker Scientific Instruments (BSI) book-to-bill greater than one.

Frank H. Laukien, President and CEO

With BSI organic bookings and backlog both up mid-single digits % year-to-date, we expect revenue growth acceleration, continued margin expansion and double-digit EPS growth in FY27.

Frank H. Laukien, President and CEO

Not in the filing

stated, not guessed
  • Q3-26 GAAP and non-GAAP income tax expense or benefit was not separately presented as a reconciled non-GAAP income tax expense or benefit line item.
  • Q3-26 capital repurchases were not reported.
  • Q3-26 total debt was not reported as a single total-debt figure.
  • Q3-26 gross margin guidance, operating expense guidance, and tax-rate guidance were not provided.
  • Prior-quarter comparisons for reported Q3-26 metrics were not provided.
  • Year-over-year percentage changes for Bruker BIOS, Bruker MID, and Bruker Nano revenue were not printed.
  • Revenue or earnings contribution drivers for Bruker BIOS, Bruker MID, and Bruker Nano were not separately stated.
  • The previous outlook covered the full year 2026 only, so there is nothing to compare for this quarter.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

The filing is Bruker's quarterly earnings release filed on Form 8‑K, providing the first public disclosure of Q3‑26 financials and FY26 outlook.

Company-level read

Ticker impact

$BRKRBullishHigh confidence
Context

Bruker Corp disclosed Q3‑26 results and reaffirmed FY26 revenue and non‑GAAP EPS guidance in an 8‑K filing.

Expected impact

potential upside as investors price in improved margins and steady outlook

Evidence & confidence

The company reported higher non‑GAAP EPS, a 400 bps margin increase, and reaffirmed FY26 revenue/EPS targets, indicating operational strength.

Market effects

Positive for scientific instruments and life‑science diagnostics sector as Bruker signals continued growth.

Limited to U.S. and European investors tracking biotech and instrumentation stocks.

Modest, as Bruker is a niche player with no broad macro impact.

Counterpoint

If the market has already priced in the margin improvement, the reaffirmed guidance may be insufficient to drive further upside.

Key entities

  • Bruker Corp

    Manufacturer of scientific instruments and diagnostic solutions.

Every BRKR earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$BRKRMed

Bruker Scientific Instruments BioSpin BSI Chemicals, Applied Markets, Life Sciences, In Vitro Diagnostics, Detection Bruker Energy & Supercon Technologies…

BRUKER CORP (BRKR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 As Reported As Recast Bruker Scientific Instruments ("BSI") BioSpin BSI Chemicals, Applied Markets, Life Sciences, In Vitro Diagnostics, Detection ("BSI CALID") BSI NANO Bruker Energy & Supercon Technologies ("BEST") Corporate Total BSI Biosystems ("BIOS") BSI Microb

$BRKRHighAI 8/10

Bruker Corp (BRKR) Q3 2026 Earnings Call Highlights: Margin Expansion and Strong

Bruker Corp (BRKR) reported Q3 2026 with 0.7% organic revenue growth, but significant margin expansion, with non-GAAP gross margin up 120 bps to 51.3% and operating margin up 400 bps to 16.3%. Non-GAAP EPS grew 24% year-over-year to $0.56. Bookings trends remained positive, with BSI book-to-bill above 1 for five quarters. However, semiconductor metrology and NMR faced pushouts, and a $175 million goodwill impairment charge was recorded.

$BRKRHighAI 9/10

Why is Bruker stock surging today?

Bruker (BRKR) stock rose 14.2% after reporting Q3 2026 earnings of $0.56 per share, beating estimates by 33%, with revenue at $874M. Non-GAAP operating margin expanded 400 bps to 16.3%. Jefferies raised its price target to $70. Management reconfirmed full-year EPS guidance of $2.10–$2.15. The stock hit a 52-week high of $68.98.

$BRKRMed

Bruker (BRKR) Q3 2026 Earnings Call Transcript

Bruker (BRKR) reported Q3 2026 revenues of $874M, up 1.6% YoY, with non-GAAP EPS of $0.56, up 24%. CEO Frank Laukien highlighted growth in U.S. academic/government, China, and semiconductor metrology markets. The company expects revenue acceleration and margin expansion, driven by strong bookings trends and strategic investments in AI and organ-on-a-chip technologies.

$BRKRMed

Bruker Corporation Q3 2026 Earnings Call Summary

Bruker Corporation reported Q3 2026 earnings with 400 basis points year-over-year non-GAAP operating margin expansion. The BSI segment had a book-to-bill ratio over one for five quarters, and China BSI organic bookings grew over 20%. Management reconfirmed full-year 2026 organic revenue growth of 1% to 2% and non-GAAP EPS of $2.10 to $2.15. They expect double-digit EPS growth and at least 100 basis points of further operating margin expansion for fiscal year 2027.